Homologous Recombination Deficiencies and Hereditary Tumors

Int J Mol Sci. 2021 Dec 29;23(1):348. doi: 10.3390/ijms23010348.

Abstract

Homologous recombination (HR) is a vital process for repairing DNA double-strand breaks. Germline variants in the HR pathway, comprising at least 10 genes, such as BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, NBS1(NBN), PALB2, RAD51C, and RAD51D, lead to inherited susceptibility to specific types of cancers, including those of the breast, ovaries, prostate, and pancreas. The penetrance of germline pathogenic variants of each gene varies, whereas all their associated protein products are indispensable for maintaining a high-fidelity DNA repair system by HR. The present review summarizes the basic molecular mechanisms and components that collectively play a role in maintaining genomic integrity against DNA double-strand damage and their clinical implications on each type of hereditary tumor.

Keywords: BRCAness; cancer predisposition; germline; hereditary tumor; homologous recombination deficiency (HRD); multi-gene panel testing (MGPT).

Publication types

  • Review

MeSH terms

  • Genetic Predisposition to Disease
  • Genetic Testing
  • Germ-Line Mutation / genetics
  • Homologous Recombination / genetics*
  • Humans
  • Neoplasms / diagnosis
  • Neoplasms / genetics*
  • Precision Medicine